Stock AnalizCelldex Therapeutics, Inc. CLDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances · data as of November 13, 2026
Celldex Therapeutics, Inc. (CLDX) is a healthcare company listed in the US with a market value of about $2.3B. In the twelve months to September 30, 2026 it had revenue of $158000 and net income of -$309M, a net margin of -195608.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -27% a year, a 5-year average ROIC of -32%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158000 | $2M | $7M | $7M | $2M | $5M | $7M | $4M | $10M | $13M | $7M |
| Net income | -$309M | -$259M | -$158M | -$141M | -$112M | -$71M | -$60M | -$51M | -$151M | -$93M | -$129M |
| Free cash flow | -$260M | -$214M | -$160M | -$109M | -$106M | -$62M | -$42M | -$47M | -$76M | -$102M | -$116M |
| EPS (diluted) | $-3.94 | $-3.90 | $-2.45 | $-2.92 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.01 | $-10.86 | $-18.99 |
| Net margin | -195608.9% | -16748.0% | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% | -1424.0% | -1585.1% | -730.1% | -1894.0% |
| ROIC | — | -54.3% | -26.0% | -35.8% | -27.6% | -16.8% | -29.2% | -44.5% | -125.5% | -40.8% | -39.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $64.00, 122% above the current price; targets range from $29.00 to $100.00; the consensus rating is “Strong buy”; expected EPS is $-4.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Celldex Therapeutics pay a dividend?
Not currently.
Is Celldex Therapeutics a good stock to buy?
We do not give buy or sell advice. Celldex Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.